Since Doug Williams signed on as Executive Vice President of Research and Development at Biogen Idec in 2011, the company has had a string of successes. Its oral multiple sclerosis drug Tecfidera has snagged a spot as one of the best launches ever, with well over US$1 billion in its first full four quarters of sales, and a recent pair of long-acting haemophilia drug approvals are set to shake up the haematology market. Future growth could come from remyelinating agents, Alzheimer's disease drugs and gene therapy, Williams tells Asher Mullard.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Doug Williams. Nat Rev Drug Discov 13, 880–881 (2014). https://doi.org/10.1038/nrd4496
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4496
